Caris Life Sciences, Inc.
CAIHealthcare|Biotechnology|US
$25.23
-0.80 (-3.07%)
Tangible Book / Share
$2.18
Graham Number
$4.14
Cash / Share
$2.70
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03870620 Metastatic Breast Cancer in Austria | Breast Cancer, Breast Carcinoma | Recruiting | 5,000 | — | — | |
| NCT02967770 Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | P2 | Withdrawn | — | RCT, Open-label | Standard of Care Second Line Therapy |
| NCT03834220 Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | Solid Tumor | P2 | Terminated | 63 | Open-label | Debio 1347 |
| NCT05692466 Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur") | Stage III Solid Tumors, Stage IV Solid Tumors | Unknown | 572 | — | — |